SecBot SecBot

MBRX

Moleculin Biotech, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001659617 Biotech & Drug Discovery
$6.89 +0.39 (+6.00%)
Oct 26 4:00 PM ET · prev $6.50
Market cap
$6.2M
Nano cap
Consensus
Buy
89% Buy or better · 9 analysts
Median target
$60.00
+771% · range $40.00–620.00
Next earnings
Nov 11
in 16 days · EPS est. −$8.87
1 year
−44.4%
from $12.40 · Oct 27
30 days
+1110.9%
from $0.5690
52-week range
$0.2800–15.60
−56% from high · low Oct 16
Avg volume 20D
329.7K
Sep 29 spike 1.66M
Short interest
204.6K
≈1.0% of shares · −28.9%
Days to cover
1.0
at average volume
Insider net
$0.00
3 buyers · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
SecBot read MIXED 16 reports · 90 days
Balance 4 bearish · 4 bullish · 2 mixed · 6 neutral oldest → newest, height = score
Avg score ·High conf. 10/16 ·Next Earnings date, Nov 11, 2026
Strongest BEARISH Moleculin Biotech received a Nasdaq Staff Determination Letter on September 15, 2026, stating that its…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersMIXED

    No open-market sales.

  • InstitutionsBULLISH

    Q2 2026: 5 added (0 new), 0 trimmed or exited.

  • AnalystsBULLISH

    8 of 9 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$21.400 → −$8.867 over 90 days. 1 up, 0 down in 30 days.

  • Short sellersCOVERING

    Short interest −28.9% to 204.6K shares. 1.0 days to cover, ≈1.0% of shares.

  • TrendRANGE

    139% above its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
GEODE CAPITAL MANAGEMENT, LLCADD47,252$131.8K
VANGUARD CAPITAL MANAGEMENT LLCDOUBLED42,215$117.8K
VANGUARD FIDUCIARY TRUST CODOUBLED29,883$83.4K
MORGAN STANLEYDOUBLED20,036$55.9K
Rockefeller Capital Management L.P.DOUBLED15,000$41.9K
GEODE CAPITAL MANAGEMENT, LLCDOUBLED32,329$74.0K
Rockefeller Capital Management L.P.DOUBLED4,421$10.1K
UBS Group AGTRIM3,409$7.8K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

9 analysts
Buy 89% rate it Buy or better
Strong Buy2Buy6Hold1Sell0Strong Sell0
12-month targets · 3 analysts

Price is below the lowest target. Median implies +771%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Aug 28, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 11, 2026
Earnings date
MBRX Q3 2026 Earnings Scheduled — 2026-11-11
Recent
Oct 20, 2026
Trading halt
Halt Resumed: MBRX — trading resumed after T3 (News and Resumption Times)
Halted 2026-10-19T23:50:00.000Z | Resumed 2026-10-20T13:00:00.000Z
Oct 19, 2026
Trading halt
Trading Halt: MBRX — T1 (News Pending)
Moleculin Biotech, Inc. COM | Market: NASDAQ | Code: T1 — News Pending
Oct 19, 2026
Trading halt
Trading Halt: MBRX — T3 (News and Resumption Times)
Moleculin Biotech, Inc. COM | Market: NASDAQ | Code: T3 — News and Resumption Times
Sep 29, 2026
Earnings
Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout
HOUSTON, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced that it has…
Sep 28, 2026
Press release
Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine
– Pooled analysis of five clinical trials found no clinical or subclinical evidence of cardiotoxicity at cumulative doses exceeding traditional…

Insider ledger

Form 4
$0
bought · 3 insiders
$0
sold · 0 insiders
DateInsiderTypeValue
Oct 15, 2026
Foster Jonathan P.
Chief Financial Officer
TAX W/H$11.3K
Oct 15, 2026
PICKER DONALD H
Chief Science Officer
AWARD250,000 sh
Oct 15, 2026
Foster Jonathan P.
Chief Financial Officer
EXERCISE130,000 sh
Oct 15, 2026
Foster Jonathan P.
Chief Financial Officer
AWARD260,000 sh
Oct 15, 2026
KLEMP WALTER V
CEO and President
TAX W/H$18.0K
Oct 15, 2026
Foster Jonathan P.
Chief Financial Officer
AWARD260,000 sh
Oct 15, 2026
KLEMP WALTER V
CEO and President
EXERCISE207,500 sh
Oct 15, 2026
KLEMP WALTER V
CEO and President
AWARD415,000 sh

Earnings setup

Estimates
Nov 11
reports in 16 days
−$8.87
EPS estimate, this quarter
+59%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$8.87-$10.80–-$6.80+56.3%$0.00
Next Q-$8.53-$9.40–-$8.00+37.7%$0.00
Current FY-$65.33-$70.60–-$58.80+39.6%$0.00
Next FY-$23.40-$32.20–-$14.00+69.6%$0.00

Short side

FINRA· Sep 30, 2026
204,583
shares short
-28.9%
vs prior settlement
1.0
days to cover
≈1.0%
of shares outstanding
Trading halts
Oct 19, 2026Resumption ScheduledResumed
Jul 31, 2026Volatility PauseResumed
Jul 31, 2026Volatility PauseResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 20, 2026 Trading halt
Halt Resumed: MBRX — trading resumed after T3 (News and Resumption Times)
Halted 2026-10-19T23:50:00.000Z | Resumed 2026-10-20T13:00:00.000Z
Oct 20, 2026 SEC
Moleculin Biotech filed an 8-K to announce a 1-for-20 reverse stock split, effective October 20, 2026, reducing…
8-K — Impact 4/10
Oct 16, 2026 SEC
Moleculin Biotech filed an 8-K on October 16, 2026, to furnish a corporate investor presentation (Exhibit 99.1) posted…
8-K — Impact 3/10
Oct 15, 2026 Insider
Foster Jonathan P. surrendered for taxes 30,485 shares
Chief Financial Officer @ $0.3701 ($11.3K)
Oct 15, 2026 Insider
PICKER DONALD H was granted 250,000 shares
Chief Science Officer
Oct 15, 2026 Insider
Foster Jonathan P. acquired via exercise 130,000 shares
Chief Financial Officer
Oct 9, 2026 SEC
Moleculin Biotech held its 2026 Annual Meeting on October 9, 2026. Stockholders approved an amendment to the 2024…
8-K — Impact 4/10
Jun 30, 2026 Inst.
GEODE CAPITAL MANAGEMENT, LLC — ADD
47,252 shares ($131.8K)

SecBot reports

29 filings · 1 press release · 9 bullish · 7 bearish · 3 mixed · 10 neutral
All MBRX filing & press-release reports (30)